Epicrispr and Infinimmune secure $165 million in venture funding for epigenetic and antibody programs

Epicrispr Biotechnologies announced a $90 million Series C round to push its epigenetic therapy program for facioscapulohumeral muscular dystrophy (FSHD).

The lead candidate, EPI-321, is in a first‑in‑human study that has completed enrollment, with results expected later this year. Early data from three patients showed an average increase in lean muscle volume of about 370 mL.

Infinimmune raised the remainder of the combined $165 million to advance two antibody candidates targeting atopic dermatitis.

Both companies plan to use the capital to advance their pipelines, with Epicrispr focusing on a one‑time AAV‑based delivery to suppress the DUX4 gene in muscle, and Infinimmune moving its antibodies toward later‑stage development.